EBI3 polyclonal, anti-human, mouse, rat

Protein Family: Enzymes

Pathway and Disease: Signaling Molecules and Interaction

Description:
EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35 (1-3). Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naïve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.

Alternate Names: EBI3 , Epstein-Barr virus induced 3 precursor, interleukin-27 subunit beta, IL-27B

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500

Accession No.: NP_005746

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human EBI3.

Format: Each vial contains 0.1 ml IgG in PBS pH 7.4 with 0.02% sodium azide. Antibody was purified by immunogen affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.